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World AIDS Day — December 1, 2014
World AIDS Day draws attention to the current status of 
the human immunodeficiency virus/acquired immunode-
ficiency syndrome (HIV/AIDS) epidemic worldwide. The 
theme for this year’s observance on December 1 is “Focus, 
Partner, Achieve: An AIDS-Free Generation.”
The first cases of AIDS were reported more than 30 years 
ago in the June 5, 1981 issue of MMWR. Today, an estimated 
35 million persons are living with HIV infection (1). Although 
AIDS-related deaths have fallen by 35% since 2005, an esti-
mated 1.5 million persons died from AIDS in 2013 (1).
Global efforts, including the President’s Emergency Plan 
for AIDS Relief (in which CDC is a principal agency), 
have resulted in approximately 11.7 million persons in 
low-income and middle-income countries receiving anti-
retroviral therapy for HIV infection in 2013 (1). This is 
nearly 2 million more persons than in 2012 (1).
In the United States, nearly 648,500 persons diagnosed 
with AIDS have died since the first cases were reported 
(2), and approximately 50,000 persons become infected 
with HIV each year (3). An estimated 1.2 million persons 
in the United States are living with HIV infection (4).
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Although scale-up of antiretroviral therapy (ART) since 
2005 has contributed to declines of about 30% in the global 
annual number of human immunodeficiency (HIV)-related 
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deaths and declines in global HIV incidence,* estimated 
annual HIV-related deaths among adolescents have increased 
by about 50% (1) and estimated adolescent HIV incidence has 
been relatively stable.† In 2012, an estimated 2,500 (40%) of 
all 6,300 daily new HIV infections occurred among persons 
aged 15–24 years.§ Difficulty enrolling adolescents and young 
adults in ART and high rates of loss to follow-up (LTFU) after 
ART initiation might be contributing to mortality and HIV 
incidence in this age group, but data are limited (2). To evaluate 
age-related ART retention challenges, data from retrospective 
cohort studies conducted in seven African countries among 
16,421 patients, aged ≥15 years at enrollment, who initiated 
ART during 2004–2012 were analyzed. ART enrollment and 
outcome data were compared among three groups defined by 
age at enrollment: adolescents and young adults (aged 15–24 
years), middle-aged adults (aged 25–49 years), and older adults 
(aged ≥50 years). Enrollees aged 15–24 years were predomi-
nantly female (81%–92%), commonly pregnant (3%–32% of 
females), unmarried (54%–73%), and, in four countries with 
employment data, unemployed (53%–86%). In comparison, 
older adults were more likely to be male (p<0.001), employed 
(p<0.001), and married, (p<0.05 in five countries). Compared 
with older adults, adolescents and young adults had higher 
LTFU rates in all seven countries, reaching statistical signifi-
cance in three countries in crude and multivariable analyses. 
Evidence-based interventions to reduce LTFU for adolescent 
and young adult ART enrollees could help reduce mortality 
and HIV incidence in this age group.
In each of seven countries (Côte d’Ivoire, Nigeria, Swaziland, 
Mozambique, Zambia, Uganda, and Tanzania), a representative 
sample of ART facilities was selected using either probability-
proportional-to-size sampling or purposeful (nonrandom) 
sampling (Table 1). At each selected facility, a sample frame of 
study-eligible ART patients was created, and simple random 
sampling used to select the desired sample size. Eligibility 
criteria included having started ART during 2004–2012 and 
≥6 months before data abstraction. Data were abstracted from 
ART medical records onto standard forms.
Mortality and LTFU were the primary outcomes of interest. 
A patient was considered LTFU if he/she had not attended the 
facility in the 90 days preceding data abstraction for a medi-
cation refill, a laboratory visit, or a clinician visit. Mortality 
ascertainment occurred largely through passive reporting to 
the health facility by family or friends, and to a lesser extent, 
through country-specific tracing activities to locate patients 
late for clinic appointments. 
Study design was controlled for during analysis. Age at ART 
initiation was divided into three age categories (3): 15–24 years, 
* Information available at http://www.unaids.org/en/media/unaids/contentassets/
documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf.
† Sources: Kasedde S, Luo C, McClure C, Chandan U. Reducing HIV and AIDS 
in adolescents: opportunities and challenges. Curr HIV/AIDS Rep 2013;10:159–68; 
and UNAIDS. Report on the Global AIDS Epidemic, 2012, unpublished estimates; 
Spectrum 2012.
§ Information available at http://www.unaids.org/sites/default/files/en/media/
una ids /contenta s se t s /documents /ep idemio logy/2012/gr2012/
JC2434_WorldAIDSday_results_en.pdf.
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25–49 years, and ≥50 years. Differences in demographic and 
clinical characteristics across age groups were assessed using 
chi-square tests for categorical variables and unadjusted linear 
regression models for continuous variables. 
To estimate the association between age group and rates of 
death and LTFU, Cox proportional hazards regression models 
were used to estimate unadjusted and adjusted hazard ratios for 
each outcome separately. For the multivariable analysis, to best 
manage missing baseline demographic or clinical data, multiple 
imputation with chained equations was used to impute missing 
data included in the model (4). Twenty imputed datasets were 
created for each outcome: death and LTFU (4). The imputa-
tion model included the event indicator, all study variables, 
and the Nelson-Aalen estimate of cumulative hazard (4). The 
proportional hazards assumption was assessed using visual 
methods and the Grambsch and Therneu test. 
Demographic and clinical characteristics of adults at ART ini-
tiation were compared across age groups by country (Table 2). 
Age distribution was relatively constant across countries, with 
5%–16% aged 15–24 years, 70%–86% aged 25–49 years, and 
8%–14% aged ≥50 years. In all seven countries, the youngest 
age group was almost exclusively female (81%–92%), and the 
TABLE 1. Summary of sampling strategies to select cohorts of enrollees for antiretroviral therapy (ART) — seven African countries, 
2004–2013
Region and 
country 
Stage 1: Selection of study facilities Stage 2: Selection of study patients
No. of 
ART 
clinics 
No. of  
ART 
enrollees 
at  
ART 
clinics
Clinic 
eligibility 
criteria  
for  
study
No. of 
study-
eligible 
clinics
Estimated 
no. of 
study-
eligible 
adult ART 
enrollees 
at 
study-
eligible 
clinics 
Site 
sampling 
technique
No. of 
clinics 
selected
Age-
eligibility 
criteria 
(age at  
ART 
initiation)
ART 
enrollment 
years
Patient 
sampling 
technique 
at  
selected 
study 
clinics
Planned 
sample 
size
No. of 
eligible 
patient 
charts 
abstracted
Date of 
data 
collection
West Africa
Côte d’Ivoire 124 by 
Dec 
2007
36,943 Enrolled 
≥50 adults 
by Dec 
2007
78 36,110 PPS 34 Adults 
aged  
≥15 yrs 
2004–2007 SRS 4,000 3,682 Nov 2009–
March 2010
Nigeria 178 by 
Dec 
2009
168,335 Enrolled 
≥50 adults 
by Dec 
2009
139 167,438 PPS 35 Adults 
aged  
≥15 yrs
2004–2012 SRS 3,500 3,496 Dec 2012–
Aug 2013
Southern Africa
Swaziland 31 by 
Dec 
2009
50,767 All ART 
initiation 
sites 
eligible
31 50,767 PPS 16 Adults 
aged  
≥15 yrs
2004–2010 SRS 2,500 2,510 Nov 2011– 
Feb 2012
Mozambique 152 by 
Dec 
2006
43,295 Enrolled 
≥50 adults 
by Dec 
2006
94 42,234 PPS 30 Adults 
aged  
≥15 yrs
2004–2007 SRS 2,600 2,596 Sept–Nov 
2008
Zambia 322 by 
Dec 
2007
65,383 Enrolled 
≥300 
adults by 
Dec 2007
129* 58,845* Purposeful 6 Adults 
aged  
≥15 yrs
2004–2009 SRS 1,500 1,214† April–July 
2010
East Africa
Uganda 286 by 
Dec 
2007
45,946 Enrolled 
≥300 
adults by 
Dec 2007
114* 41,351* Purposeful 6 Adults 
aged  
≥15 yrs
2004–2009 SRS 1,500 1,466§ April–July 
2010
Tanzania 210 by 
Dec 
2007
41,920 Enrolled 
≥300 
adults by 
Dec 2007
85 37,728* Purposeful 6 Adults 
aged  
≥18 yrs
2004–2009 SRS 1,500 1,457¶ April–July 
2010
Total   452,589  670 434,473 133 17,100 16,421
Abbreviations: PPS = probability-proportional-to-size; SRS = simple random sampling.
* Estimates based on available published data.
† In Zambia, from 1,457 records sampled, 243 were excluded because of noncompliance with simple random sampling procedures at one site.
§ In Uganda, from 1,472 records samples, six patients were excluded because of absence of age data at ART initiation.
¶ In Tanzania, from 1,458 records samples, one patient was excluded because of absence of age data at ART initiation.
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middle-age group mostly female (60%–68%); in contrast, 
the oldest age group was mostly male in all countries, except 
Nigeria. In the six countries with data on pregnancy at ART 
enrollment, pregnancy prevalence was highest in the youngest 
age group in five countries, where it ranged from 16% to 32%. 
In all seven countries, being married or in a civil union was 
least common in the youngest age group (27%–46%), reaching 
statistical significance in five countries. In the four countries 
TABLE 2. Demographic and clinical characteristics of patients at initiation of antiretroviral therapy (ART) — seven African countries, 
2004–2012*
Characteristic and  
age group (yrs) 
Côte d’Ivoire†
(N = 3,682)
Nigeria†
(N = 3,496)
Swaziland†
(N = 2,510)
Mozambique†
(N = 2,596)
Zambia
(N = 1,214)
Tanzania
(N = 1,457 )
Uganda
(N = 1,466)
Age at ART initiation (No. and %)
15–24  188 5%  399 11% 398 16%  284 12% 95 8% 83 6% 95 6%
25–49  3,087 83%  2,805 81% 1,759 70%  2,069 79% 1,000 82% 1,198 82% 1,261 86%
≥50  407 12%  292 9% 353 14%  243 10% 119 10% 176 12% 110 8%
Female (No. and %)
15–24  166 87% 366 92% 326 82%  45 86% 82 86% 73 88% 77 81%
25–49  2,077 68% 1,808 64% 1,120 64%  838 60% 599 60% 813 68% 837 66%
≥50  179 46% 146 51% 175 49%  137 48% 45 38% 87 49% 50 45%
p–value <0.001§ <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Among females, pregnant (No. and %)
15–24 4 3% 56 16% 82 26% 61 30% 15 32% — 25 18%
25–49 64 4% 188 10% 117 11% 138 14% 56 12% — 102 9%
≥50 0 0% 0 0% 2 1% 0 0% 0 0% — 0 0%
p-value 0.567 <0.001 <0.001 0.002 0.003 <0.001
Married/Civil union (No. and %)
15–24  41 27% 177 43%  85 28%  99 41% 38 46% 28 41% 21 34%
25–49  1,393 50% 1,795 64%  725 47%  999 55% 520 60% 505 53% 431 43%
≥50  202 54% 200 67%  190 65%  113 55% 67 64% 71 49% 40 43%
Missing  414 11% 86 2%  384 15% 233 9% 166 14% 299 21% 313 21%
p-value <0.001 <0.001 <0.001 0.001 0.022 0.115 0.354
Employed (No. and %)
15–24  59 47%  91 30% 68 31%  28 14% — — —
25–49  1,394 63%  1,541 66% 551 48%  860 49% — — —
≥50  148 53%  165 70% 73 32%  104 56% — — —
Missing  1,081 29%  420 12% 925 37% 328 13%            
p-value <0.001 <0.001 <0.001 <0.001      
Baseline weight (No. and median [kg])
15–24  162 49.0 371 52.0 356 58.0  223 50.0  83 49.0  80 48.2  86 52.7
25–49  2,743 53.0 2589 57.0 1575 60.0  1,658 54.5  882 53.0  1,163 51.1  1,145 55.0
≥50  351 54.0 274 57.0 301 59.9  180 52.5  108 55.0  172 50.2  101 56.0
Missing  426 12% 262 7% 278 11%  535 21%  141 12%  42 3%  134 9%
p-value 0.005 <0.001 0.024 0.015 0.001 0.296 0.001
WHO clinical stage 4 (No. and %)
15–24 25 18% 25 5% 22 6%  32 20% 11 13% 20 29%  12 14%
25–49 462 22% 197 8% 218 13%  205 15% 96 11% 257 27%  137 12%
≥50 67 25% 24 11% 53 16%  22 15% 5 5% 48 35%  11 12%
Missing 1,101 30% 232 7% 290 12%  979 38% 157 13% 293 20%  164 11%
p-value 0.468 0.012 <0.001 0.066 0.100 <0.001 0.551
Baseline CD4 count (No. and median [cells/µL])
15–24  165 122 320 192 359 158  249 175 69 147 50 175  76 161
25–49  2,811 136 2321 157 1618 141  1,794 157  701 128  933 126  1,011 133
≥50  367 132 244 142 319 160  211 133  79 158 137 160  79 147
Missing  339 9% 611 17% 214 9%  342 13% 365 30%  337 23%  300 20%
p-value 0.216 0.004 0.139 0.077 0.704 0.243 0.501
Baseline hemoglobin (No. and median [g/dL])
15–24  156 10.0  190 10.3 229 10.7  211 9.4 52 10.1  37  9.6  55 11.5
25–49  2,646 9.9  1,365 10.3 1165 11.2  1,515 10.2 582 10.6 648  10.2  748 11.9
≥50  347 9.9  145 10.8 218 11.6  173 10.6 70 11.6 90  10.9  62 12.1
Missing  533 14%  1,796 51% 898 36%  697 27% 510 42% 682 47%  601 41%
p-value 0.524 0.690 <0.001 <0.001 0.002 0.028 0.306
Abbreviation: WHO = World Health Organization.
* Although the study captured patient follow-up time through 2013, all patients started ART during the period 2004–2012.
† Proportions from Côte d’Ivoire, Nigeria, Swaziland, and Mozambique are weighted to account for sampling design.
† Bold-typed p-values are statistically significant (p<0.05).  
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with data on employment status, the youngest age group was 
least likely to be employed at the time of ART enrollment 
(14%–47%) (p<0.05). 
In all seven countries, median baseline weight was lowest 
in the youngest age group (48.2–58.0 kg), reaching statisti-
cal significance in six countries. In three countries (Nigeria, 
Swaziland, and Tanzania), prevalence of World Health 
Organization clinical stage 4 at ART initiation differed across 
age groups, tending to be lowest in the youngest and highest in 
the oldest age group (p<0.05). Median baseline CD4 count was 
similar across age groups in all countries, except Nigeria, where 
the median was highest in the youngest age group (p=0.004). 
Median baseline hemoglobin was significantly lower in the 
youngest age group in four countries (9.4–10.7 g/dL). 
Compared with older adults, rates of LTFU were higher 
in the youngest age group in all seven countries, reaching 
statistical significance in unadjusted analyses in three coun-
tries (Côte d’Ivoire (p=0.005), Mozambique (p<0.001), and 
Tanzania (p=0.005)) (Table 3). Even after adjusting for baseline 
demographic and clinical characteristics, rates of LTFU were 
1.66–2.45 times as high in the youngest compared with 
the oldest age group in these three countries (Côte d’Ivoire 
[p=0.001], Mozambique [p=0.002], and Tanzania [p<0.001]). 
In two countries (Swaziland and Uganda), the oldest age 
group had significantly higher rates of documented mortality 
than younger age groups (Table 3), and older age remained a 
significant predictor of mortality even in multivariable analyses. 
Discussion
The three main findings based on the experience of the seven 
African countries are as follows: 1) adolescents and young 
adults differed significantly from older adults in ART enroll-
ment characteristics; 2) adolescents and young adults tended 
to have higher LTFU rates; and 3) in two countries (Uganda 
and Swaziland), adults ≥50 years had higher documented 
mortality rates.
Adolescent and young adult ART enrollees were almost 
exclusively female, commonly pregnant, unmarried, and 
unemployed. The observation that median weight was lowest 
among adolescents and young adults could be explained by 
expected weight-for-age growth, sex differences in weight, 
or undernutrition. Similarly, the observation that median 
hemoglobin tended to be lowest in the youngest age group 
might reflect predominantly female sex or higher prevalence 
of undernutrition. 
Available data suggest that this group of predominantly 
female adolescent and young adult ART enrollees represents 
a socially vulnerable population (2). Although rates of HIV-
related mortality and HIV incidence have declined globally 
since 2005, mortality has increased and HIV incidence 
remained relatively stable among adolescents, with the major-
ity of adolescent deaths and new HIV infections occurring in 
sub-Saharan Africa (2). In African countries with generalized 
epidemics, being young, female, and unemployed increases the 
risk for voluntary or coerced sexual contact with older, HIV-
infected men (2); this might partly explain HIV infection at 
a young age among some of the female adolescent and young 
adult ART enrollees described in this report. Factors that pos-
sibly explain high LTFU rates among adolescent and young 
adult ART enrollees might include stigma (2), lack of money 
for transport (5), child care responsibilities, and migration 
for work (6). LTFU from ART is associated with significant 
increases in mortality risk (7). A recent meta-analysis suggests 
that 20%–60% of patients lost to follow-up die, with most of 
these deaths occurring after default from ART (7). Therefore, 
difficulties in preventing LTFU among adolescent and young 
adults on ART might be a contributor to HIV-related mortality 
in this age group. Suboptimal ART adherence among adoles-
cents might also be contributing to adolescent mortality (1). 
What is already known on this topic?
Although scale-up of antiretroviral therapy (ART) since 2005 has 
contributed to a decline of about 30% in the global annual 
number of human immunodeficiency (HIV)–related deaths and 
declines in global HIV incidence, estimated annual HIV-related 
deaths among adolescents have increased by about 50%, and 
estimated adolescent HIV incidence has been relatively stable. 
In 2012, an estimated 2,500 (40%) of all 6,300 daily new HIV 
infections occurred among persons aged 15–24 years. Difficulty 
enrolling adolescents and young adults in ART and high rates of 
loss to follow-up (LTFU) after ART initiation might be contribut-
ing to mortality and HIV incidence in this age group, but data 
are limited.
What is added by this report?
Age-related differences in enrollment characteristics and 
outcomes were analyzed among 16,421 patients aged ≥15 
years starting ART in seven African countries (Côte d’Ivoire, 
Nigeria, Swaziland, Mozambique, Zambia, Uganda, and 
Tanzania) during 2004–2012. Patient characteristics and 
outcomes were compared across three age groups: adolescents 
and young adults (15–24 years), middle-aged adults (25–49 
years), and older adults (≥50 years). Compared with older 
adults, adolescents and young adults had higher LTFU rates in 
all seven countries, reaching statistical significance in three 
countries (Côte d’Ivoire, Mozambique, and Tanzania) in both 
crude and multivariable analyses.
What are the implications for public health practice?
The higher risk for LTFU among adolescent and young adult 
ART enrollees, compared with older adults, increases their risk 
for death and increases the risk they will transmit HIV to 
seronegative sex partners. Effective interventions to reduce 
LTFU for adolescent and young adult ART enrollees could help 
reduce mortality and lower HIV incidence in this age group.
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High rates of LTFU among adolescent and young adult ART 
enrollees is also concerning from a prevention perspective, 
because LTFU patients are at risk for transmitting HIV to 
seronegative partners once ART is discontinued and viral load 
no longer suppressed (8). High rates of LTFU among young 
women, among whom the prevalence of pregnancy is high, also 
increases the likelihood of mother-to-child HIV transmission. 
Adult ART enrollees aged ≥50 years were mostly male, 
commonly married, and employed. In two countries, this age 
group had higher documented mortality, similar to findings 
in other studies (9). Higher mortality in this oldest age group 
should probably be expected because of higher background 
rates of mortality in the older general population. However, 
HIV-related reasons for higher mortality in the oldest age group 
might include slower ART-induced CD4 restoration among 
older patients (3) or incidence of HIV-associated noncommu-
nicable diseases, especially atherosclerotic disease (10).
The findings in this report are subject to at least four limita-
tions. First, missing data might have introduced nondifferential 
measurement error. Second, because of differences in cohort 
size, there was greater power to detect covariate effect sizes in 
Côte d’Ivoire, Nigeria, Swaziland, and Mozambique than in 
Zambia, Uganda, and Tanzania. Third, in Zambia, Uganda, 
and Tanzania, clinics were purposefully selected, limiting 
generalizability of findings. Finally, limited active tracing for 
defaulting patients might have resulted in overestimates of 
LTFU and underestimates of mortality.
The main finding of this report is that adolescent and young 
adult ART enrollees differ significantly from older adults in 
demographic and clinical characteristics and are at higher 
risk for LTFU. Effective interventions to reduce LTFU for 
adolescent and young adult ART enrollees could help reduce 
mortality and HIV incidence in this age group.
TABLE 3. Association between age group at initiation of antiretroviral therapy and rates of loss to follow-up and death — seven African countries, 2004–2013
Country 
 Age group 
(yrs)  No. 
Lost to follow-up Died
Rate  
(per 100) 
Crude Adjusted 
Rate  
(per 100) 
Crude Adjusted
HR (95% CI) p-value AHR* (95% CI) p-value HR (95% CI) p-value AHR* (95% CI) p-value
Côte d’Ivoire 
  ≥50 407 14.5  1.00 — — 1.00 — — 4.2  1.00 — —  1.00 — —
  25–49 3,087 17.5 1.21 (0.92–1.59)  0.171 1.33 (1.00–1.77) 0.052† 2.9 0.68 (0.45–1.05) 0.077 0.76 (0.51–1.12) 0.155
  15–24 188 23.0 1.54 (1.15–2.04)  0.005 1.66 (1.24–2.22) 0.001 3.8 0.87 (0.37–2.03) 0.732 0.97 (0.43–2.18) 0.935
Nigeria 
  ≥50 399 15.3  1.00 — — 1.00 — — 1.5  1.00 — —  1.00 — —
  25–49 2,805 13.7 0.91 (0.70–1.18) 0.446 0.94 (0.73–1.22) 0.640 1.1 0.79 (0.43–1.46) 0.441 0.89 (0.47–1.68) 0.714
  15–24 292 16.5 1.09 (0.79–1.50) 0.604 1.04 (0.75–1.44) 0.818 0.8 0.51 (0.20–1.34) 0.166 0.74 (0.30–1.86) 0.514
Swaziland§
≥50 353 11.0  1.00 — — 1.00 — — 3.0  1.00 — —  1.00 — —
  25–49 1,759 11.4 1.06 (0.91–1.23) 0.452 0.99 (0.81–1.20) 0.887 1.9 0.66 (0.46–0.93) 0.021 0.56 (0.39–0.81) 0.006
  15–24 398 13.2 1.26 (0.94–1.70) 0.113 1.22 (0.89–1.68) 0.198 1.9 0.65 (0.46–0.92) 0.018 0.58 (0.38–0.90) 0.019
Mozambique  
  ≥50 243 16.4  1.00 — —  1.00 — — 3.8  1.00 — —  1.00 — —
  25–49 2,069 14.4 0.96 (0.78–1.18) 0.686 1.02 (0.79–1.32) 0.872 3.2 0.94 (0.55–1.59) 0.805 1.10 (0.62–1.96) 0.733
  15–24 284 28.4 1.80 (1.46–2.21) <0.001 1.76 (1.27–2.43) 0.002 5.0 1.40 (0.72–2.71) 0.296 1.33 (0.72–2.45) 0.339
Zambia 
  ≥50 95 21.4  1.00 — —  1.00 — — 3.6  1.00 — —  1.00 — —
  25–49 1,000 21.7 1.01 (0.75–1.37) 0.928 0.94 (0.69–1.29) 0.722 2.3 0.63 (0.29–1.33) 0.223 0.66 (0.30–1.47) 0.312
  15–24 119 25.6 1.14 (0.75–1.74) 0.539 1.21 (0.78–1.89) 0.393 5.1 1.32 (0.49–3.51) 0.582 1.26 (0.43–3.71) 0.679
Tanzania
  ≥50 83 13.0  1.00 — —  1.00 — — 8.0  1.00 — —  1.00 — —
  25–49 1,198 17.8 1.36 (0.98–1.90) 0.067 1.47 (1.05–2.06) 0.024 6.4 0.80 (0.52–1.23) 0.309 0.90 (0.58–1.42) 0.661
  15–24 176 30.1 2.01 (1.24–3.25) 0.005 2.45 (1.50–4.01) <0.001 13.5 1.37 (0.70–2.70) 0.358 1.40 (0.69–2.82) 0.354
Uganda
  ≥50 95 6.0  1.00 — —  1.00 — — 2.8  1.00 — —  1.00 — —
  25–49 1,261 7.6 1.29 (0.76–2.17) 0.346 1.37 (0.81–2.34) 0.240 1.0 0.35 (0.15–0.80) 0.013 0.31 (0.13–0.76) 0.010
  15–24 110 7.1 1.18 (0.57–2.44) 0.664 1.19 (0.56–2.51) 0.647 1.0 0.34 (0.07–1.66) 0.184 0.25 (0.05–1.29) 0.098
Abbreviations: HR = hazard ratio; CI = confidence interval; AHR = adjusted hazard ratio.
* All variables presented in the table were included in the multivariable model for each country.
† Bold-typed p-values are statistically significant (p<0.05) or borderline significant (p=0.05–0.10).
§ In Swaziland, the study was designed to assess the effect of interfacility transfer of stable patients (down-referral) on risk for loss to follow-up, and this time-varying 
covariate was included in the multivariable model in addition to variables presented in the table.
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